Subscribe
T. Schneider / Shutterstock.com
25 February 2025NewsBiotechnologySarah Speight

Natera loses $96m jury win as judge invalidates DNA test patents

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing technology found invalid | Natera also faces separate trade secrets claims from Guardant Health over cancer blood tests.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
‘We took Ravgen head-on’: How we won zero-damages and others didn't
14 November 2024   Michael Summersgill and his co-counsel at WilmerHale secured more favourable outcomes for their clients than others in a series of lawsuits brought by Ravgen over pre-natal screening tests, he tells Sarah Speight.


Editor's picks

Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025

Editor's picks

Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025
Careers
Bristows appoints Irish patent attorney to boost UPC representation
4 February 2025
Americas
New national rankings recognise top US patent firms and lawyers
4 February 2025
Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025
Americas
ADCs, TCR, and multimodal AI: Transformative trends in 2025
23 January 2025
Americas
Trump nixes Biden’s Executive Order on drug pricing
21 January 2025

More on this story

Americas
‘We took Ravgen head-on’: How we won zero-damages and others didn't
14 November 2024   Michael Summersgill and his co-counsel at WilmerHale secured more favourable outcomes for their clients than others in a series of lawsuits brought by Ravgen over pre-natal screening tests, he tells Sarah Speight.

More on this story

Americas
‘We took Ravgen head-on’: How we won zero-damages and others didn't
14 November 2024   Michael Summersgill and his co-counsel at WilmerHale secured more favourable outcomes for their clients than others in a series of lawsuits brought by Ravgen over pre-natal screening tests, he tells Sarah Speight.

More features

Why Abbott’s victory marks a turning point for UPC preliminary injunctions
Fed Circ’s Wuhan v ITC ruling opens ITC door to small corps
Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules
Gilead deal staves off generic HIV drugs for another six years
Apple voids Omni MedSci wearable tech patent
Clifford Chance expands life sciences team with A&O Shearman hire
Vidal: ‘Erroneous’ jury instructions need to be fixed at Fed Circ
'A very good decision’: Patent industry welcomes UPC in-house reps update